Septerna, Inc. Common StockSEPN
About: Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Employees: 75
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
108% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 12
2.52% more ownership
Funds ownership: 99.38% [Q4 2024] → 101.91% (+2.52%) [Q1 2025]
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
0% more funds holding
Funds holding: 70 [Q4 2024] → 70 (+0) [Q1 2025]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 4 (-1) [Q1 2025]
65% less call options, than puts
Call options by funds: $157K | Put options by funds: $444K
74% less capital invested
Capital invested by funds: $1.01B [Q4 2024] → $262M (-$748M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Cantor Fitzgerald Josh Schimmer | 151%upside $25 | Overweight Maintained | 16 May 2025 |
Wells Fargo Derek Archila | 81%upside $18 | Equal-Weight Maintained | 16 May 2025 |
Financial journalist opinion
Based on 11 articles about SEPN published over the past 30 days









